CN1771028A - 用于治疗或预防刺激、发炎和皮肤红斑的含二甲砜的化妆品和/或药物组合物 - Google Patents
用于治疗或预防刺激、发炎和皮肤红斑的含二甲砜的化妆品和/或药物组合物 Download PDFInfo
- Publication number
- CN1771028A CN1771028A CNA038265672A CN03826567A CN1771028A CN 1771028 A CN1771028 A CN 1771028A CN A038265672 A CNA038265672 A CN A038265672A CN 03826567 A CN03826567 A CN 03826567A CN 1771028 A CN1771028 A CN 1771028A
- Authority
- CN
- China
- Prior art keywords
- acid
- dimethylsulfone
- compositions
- weight
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010015150 Erythema Diseases 0.000 title claims abstract description 40
- 231100000321 erythema Toxicity 0.000 title claims abstract description 28
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 230000007794 irritation Effects 0.000 title claims abstract 4
- 230000004054 inflammatory process Effects 0.000 title abstract description 11
- 206010061218 Inflammation Diseases 0.000 title abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 230000002265 prevention Effects 0.000 title description 3
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 64
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 230000005855 radiation Effects 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 6
- -1 monocarboxylic acid alpha hydroxy acid Chemical class 0.000 claims description 26
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 17
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 239000003410 keratolytic agent Substances 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002916 adapalene Drugs 0.000 claims description 4
- 229940025250 camphora Drugs 0.000 claims description 4
- 239000010238 camphora Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229960001679 octinoxate Drugs 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 3
- 206010040880 Skin irritation Diseases 0.000 claims description 3
- 229960002255 azelaic acid Drugs 0.000 claims description 3
- 229960001716 benzalkonium Drugs 0.000 claims description 3
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 231100000475 skin irritation Toxicity 0.000 claims description 3
- 230000036556 skin irritation Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- ZUVDVLYXIZFDRM-UHFFFAOYSA-N 2-(hydroxymethyl)-4-methylphenol Chemical compound CC1=CC=C(O)C(CO)=C1 ZUVDVLYXIZFDRM-UHFFFAOYSA-N 0.000 claims description 2
- KKJKXQYVUVWWJP-JLHYYAGUSA-N 4-[(e)-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-JLHYYAGUSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 2
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000655 ensulizole Drugs 0.000 claims description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000601 octocrylene Drugs 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001173 oxybenzone Drugs 0.000 claims description 2
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 229960001755 resorcinol Drugs 0.000 claims description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 230000000699 topical effect Effects 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000008406 cosmetic ingredient Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000005115 demineralization Methods 0.000 description 15
- 230000002328 demineralizing effect Effects 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 8
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 7
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 7
- 241000221095 Simmondsia Species 0.000 description 7
- 235000004433 Simmondsia californica Nutrition 0.000 description 7
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 7
- 230000035558 fertility Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000007764 o/w emulsion Substances 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 7
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 6
- 229940119170 jojoba wax Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000000985 reflectance spectrum Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940117360 ethyl pyruvate Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000003711 photoprotective effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- LZCLXQDLBQLTDK-UHFFFAOYSA-N lactic acid ethyl ester Natural products CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Abstract
本发明公开了用于化妆品用或药物用的新组合物,设计为外用于无损伤和损伤皮肤黏膜上以减少或抑制外源性事件(由化学试剂,药物,化妆品成分,物理因素—比如日光照射,紫外线照射,电离辐射,X射线,γ射线,激光-细菌因子,病毒因子等诱导的刺激)诱导的刺激、炎症和皮肤红斑,并光保护皮肤免受日光辐射并特异性免受A、B和C型紫外线照射诱导的损伤。更具体地,本发明涉及二甲砜在制备局部使用的药物或化妆品组合物中的应用,以预防和/或治疗上述皮肤表现。
Description
发明领域
本发明的主题是用于化妆品用或药物用的新组合物,设计为外用于无损伤和损伤皮肤黏膜上以减少或抑制外源性事件(由化学试剂,药物,化妆品成分,物理因素-比如日光照射,紫外线照射,电离辐射,X射线,γ射线,激光-细菌因子,病毒因子等诱导的刺激)诱导的刺激、炎症和皮肤红斑,并光保护皮肤免受日光辐射并特异性免受A、B和C型紫外线照射诱导的损伤。
现有技术
红斑是一种由转运到浅表真皮血管的血液的增加引起的皮肤变红。当红斑传递动脉血管的扩张时,其定义为活性的:显示鲜艳的红色肤色并可以检测局部温度的升高。钝性的红斑起因于静脉的郁滞,显示局部温度降低的蓝红色肤色。红斑具有各种大小,形状和位点;由于血流中断的体外压力而消失。它可以由于物理的(机械,热,辐射),化学的,传染性的(真菌病,小儿斑疹伤寒病),情绪的(突然的变红,局限于面部和颈部,发生于窘境时)原因而表现出来,或由药物,维生素缺乏,内分泌功能障碍引起,或者在过敏反应过程中表现出来。
炎症是一种机体对由生物因素(微生物体),化学试剂,物理-机械因素(例如外伤,辐射)或由于疾病产生的组织损伤的防御反应。它具有产生无效的或破坏性的化学的、物理的、生物的有害因素的生物学功能,并继之以修复由效应组织产生的可能损伤。各种血管的现象由化学介质(炎症介质),比如组胺,白细胞三烯,前列腺素,血栓烷,白细胞介素决定。
光保护作用包括采取能减少紫外线对皮肤有害作用的措施。
炎症和氧化物质
活性氧物质(ROS)是毒性的和高活性的分子,在产生和维持炎性过程中起重要作用。超氧化物自由基(O2°)由单核细胞、巨噬细胞和参与所述炎性过程的细胞产生,并起着放大方法本身的作用。
氢氧根(OH°)和过氧化氢基团(H2O2°)干预炎症过程并在前列腺素的代谢过程和特别是在花生四烯酸的酶代谢过程中释放。
所述炎性过程局限于真皮水平。
本发明的问题是生产用于治疗和/或预防炎症,刺激和皮肤红斑的化妆品和/或药物组合物,并光保护皮肤免受日光辐射和更具体免受由A、B和C型紫外线照射诱导的损伤。
这个问题通过诸如在附属权利要求书中描述的含有二甲砜的组合物来解决。
附图简述
图1显示了暴露于UVB照射之前(曲线a)和之后(曲线b)获得的皮肤的反射光谱;
图2显示了未处理的位点(对照)和用制剂SALDMS5处理的位点获得的红斑指数的变化量(I.E.)作为时间的函;
图3显示了由使用者使用制剂SALDMS5和使用安慰剂获得的皮肤红斑抑制的百分比(P.I.E.)。
发明详述
本发明涉及二甲砜的应用,经适当的介质处理(vehicularised)用于局部应用,以防止和/或治疗由化学,物理,细菌和病毒因子诱导的皮肤刺激。本发明中的二甲砜用来抑制由物理因素比如,但不限于尤其是当与日光过滤剂有关时的紫外线照射(日光辐射),,电离辐射,x射线,γ射线,激光(无论何种强度和性质)诱导的红斑。
所述二甲砜还用于减少由化学试剂引起的皮肤刺激,比如羧酸,二羧酸,三羧酸,单羧酸α羟酸,二羧酸α羟酸,三羧α羟酸,单羧酸β羟酸,二羧酸β羟酸,三羧酸β羟酸,间苯二酚,酚,视黄酸,adapalene,壬二酸,水杨酸,三氯乙酸,过氧化苯(benzyl peroxide)及其他可用于化妆品和/或药物领域的物质,特征在于其是潜在的刺激物。
二甲砜还被用于能够减少由天然产生的和人工来源的日光辐射和A,B和C型紫外线诱导的损伤的特异性光保护作用。
本发明尤其涉及用于上述应用的组合物,其特征在于包含重量百分比为0.5%到90%的二甲砜,优选5%到60%,更优选在以重量计的8%到30%w/w之间。使用的二甲砜的百分比通常取决于应用的血型和预定的应用是否是预防或是治疗前述的皮肤表现。
本发明范围内包含与化妆品和/或药物赋形剂有关的含有作为唯一活性成分的二甲砜的组合物,和其中二甲砜与多种试剂组合使用的组合物,所述多种试剂诸如用于进行化学换肤的角质层分离剂或日光过滤剂或用于帮助皮肤晒成黑褐色的化合物或其刺激能力应该被抵消的药物物质。
当二甲砜代表组合物的唯一活性成分时,所述组合物是抗红斑或抗刺激的,它以按重量计在0.5%到80%之间变化的量被包含在内,优选在1%到20%之间。
当二甲砜与角质层分离剂组合时,二甲砜的量包括按重量计在1%到60%之间,并且角质层分离剂的量按重量计在5%到70%之间。
当二甲砜与日光过滤剂(例如,PABA,甲基水杨醇(homosalate),樟脑,苯甲烃铵(benzalkonium),硫酸二甲酯,二苯甲酮-3,苯基苯并咪唑磺酸,丁基甲氧基二苯甲酰基甲烷,对苯二亚甲基二樟脑磺酸,苯亚甲基樟脑磺酸,氰双苯丙烯酸辛酯,甲氧基肉桂酸辛酯,聚丙烯酰胺甲基苯亚甲基,PEG-25PABA,水杨酸辛酯,辛基二甲基PABA,p-甲氧基肉桂酸异戊酯,苯甲酮-4,3-苯亚甲基樟脑,4-甲基苯亚甲基樟脑,水杨酸异丙基苯甲酯,辛基triazonesia)组合时,二甲砜的量按重量计在0.5%和50%之间,日光过滤剂的量在1%e 20%之间,并且无论如何在国际水平的各种标准允许使用的范围限制之内。
当二甲砜与对皮肤赋予刺激活性的药物活性成分(例如视黄酸,水杨酸,壬二酸,adapalene,过氧化苯(benzyl peroxide),甲硝哒唑(metronidazole),抗生素,sulphamidics,包括它们各自的盐和酯,右旋和/或左旋形式,外消旋混合物和-顺式或-反式的形式)组合时,包括的二甲砜的量按重量计在1.0%到60.0%之间,并且包括的刺激剂的量按重量计在5.0%到70%之间。
本发明的组合物通过添加溶剂比如水(尤其是脱矿物质水),醇(比如乙醇)或二醇(例如乙二醇或丙二醇)和/或赋形剂比如乳化剂,抗氧化剂,基于脂类的赋形剂(液体脂类或固体脂类),稠度因子,析出物质,防腐剂而将重量补偿至100%。尤其用于制备乳化剂,凝胶,乳膏剂,油膏,等等的这种赋形剂,是本领域技术人员公知的,因此不进一步详细描述。
实验部分
为确证本发明,报道了与评价光保护作用和紫外线照射诱导的红斑抑制作用有关的实验。
UVB照射诱发的皮肤红斑被认为是一种用于评价通过慢性和急性暴露于日光辐射产生的对皮肤损伤的良好模型。
在这个试验中,使用文献中已经报道的方案,确定了基于5%二甲砜的制剂(SALDMS5)抑制健康的志愿者由暴露于UVB照射诱导的皮肤红斑的能力。为更客观并且定量的评价,所述产生红斑的过程已经使用非侵入的技术比如反射分光光度法进行监测。
实验方案
为评价基于5%二甲砜的制剂的光保护和抗红斑的能力,采用12个健康的志愿者,并预先告知他们实验的性质和采用的方法。已经要求得到书面同意的志愿者,已经从具有II和III光类型(phototypes)的受试者中挑选出来。
已经使用Mod.UVM-57(UVP,San Gabriel,CA)紫外线灯诱导了皮肤的红斑,所述灯能够发射290-320nm内的辐射,并且峰值在302nm。对于每个受试者而言,已经初步测定最低的致红斑剂量(MED),因此,在各前臂的中部,鉴定和划分了1cm2的六个皮肤位点,被照射以引起红斑,辐照时间相当于各受试者的MED的两倍。
UVB照射后,两个位点被用作对照,因此不处理而剩余的位点用100mg处于试验阶段的制剂(SALDMS5)处理两次。该制剂使用适当的腔(Hill Top chambers-Hill Top,Cincinnati,OH)施加于皮肤位点持续三个小时。
在处理过程(三个小时)结束后,除去Hill Top Chambers后,各位点用水洗涤以除去制剂的残余并放置30分钟。用X-Rite mod.968反射分光光度计监测各位点的红斑连续60小时。所述仪器已经使用C型照明源和视角2°按照国家标准局(National Bureau)的规定的根据白度标准进行校准。将分光光度计连接到使用设备(Spectrostart)提供的软件的个人电脑,所述软件可以将皮肤的反射光谱精细调节在400-700nm区域。
图1报道了暴露于UVB照射之前(曲线a)和之后(曲线b)涉及相同皮肤位点的反射光谱。从曲线b可以确定,暴露于UVB照射的皮肤位点的反射谱显示双波段光吸收:与血红蛋白的光吸收有关的在大约400nm的单峰和在540和580nm之间的另外二重峰。
从该设备提供的光谱数据,可以使用以下等式计算对测试的各皮肤位点随时间变化的红斑指数(I.E.),该指数代表由Dawson提议用于定量监测皮肤红斑的重要参数。
在上述的等式中,将验证血红蛋白吸收峰值的这些波长(540nm,560nm,580nm)的反射的倒数的对数值相加并且减去对应的波长值(510nm和610nm)处主要由于黑色素存在而产生的吸收。
对各位点暴露于UVB照射之前确定的E.I.基值已经从在不同时间对相同的位点计算的E.I.值中扣除,如此获得计算了曲线下相应面积(AUC)的标准曲线(E.I.-时间,参见图2)。由于AUC值与红斑自身的强度和持续时间成反比,因此与产品防止红斑生成的能力成反比,所以该值对评价红斑特别重要,
因此,为更好地比较单独制剂的功效,使用下面的公式计算抑制红斑的百分比(P.I.E.):
AUC值表示处理的位点[AUC(T)]或对照位点[AUC(C)]在E.I.-时间曲线下的面积。已经使用学生t-检验方法进行结果的统计分析。
结果
图2显示了一些与受试者1有关的标准曲线,通过报道红斑指数的变化量作为未处理的位点(对照)和用SALDMS5制剂处理的这些位点的时间函数而获得。
从图2报道的致红斑过程的变化来看,与UV B照射诱导的红斑相比检验的制剂在不同程度行使的抑制效果相当显著的。
表1报道了从基于二甲砜的制剂和对于单个受试者的E.I.-时间曲线获得的平均AUC值。
从获得的结果可以看出SALDMS5制剂具有抑制UVB照射诱导的皮肤红斑的显著功效。为对评估的产品的抑制红斑能力进行定量分析,计算了抑制红斑百分比的值(P.I.E.),报道在图3中。
总之,从这个实验获得的结果来看,SALDMS5制剂具有有利的光保护作用,用于保护皮肤免受紫外线照射作用引起的变性效果。
SALDMS5制剂的高度抗红斑和光保护能力允许这种活性成分在化妆品和药物领域的有效使用,并尤其是在预防和保护免受紫外线诱导的损伤方面。
表1-获得的对照位点(未处理的)和用基于5%二甲砜的制剂处理的位点的AUC值。
受试者ABCDEFGHILMN平均值S.DP.I.E. | 对照1580.21468.51698.31152.41338.21637.51212.51692.31547.81463.01865.51545.31516.8206.3------ | SALDMS5828.4726.3864.1952.7764.5686.7921.54623.7721.6864.9786.3505.1770.5128.249.2 |
*红斑的抑制百分比
p<0.01:SALDMS5对比对照
制剂的实例
制剂1-洗剂/溶液
N°010203 | 描述二甲基异山梨醇丙酮酸二甲砜 | %w/wa40.0050.0010.00 |
制备方法:将03溶解于01,向获得的溶液中混合02。
制剂2-洗剂/溶液
N°010203 | 描述二甲基异山梨醇三氯乙酸二甲砜 | %w/wa40.0050.0010.00 |
制备方法:将03溶解于01,向获得的溶液中混合02。
制剂3-洗剂/溶液
N°01020304 | 描述二甲基异山梨醇乙醇酸二甲砜水 | %w/wa20.0050.0020.0010.00 |
制备方法:将03+02溶解于01,向获得的溶液中混合04。
制剂4-水包油乳剂
N°0102030405060708091011121314151617181920 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Toeopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯甲氧肉桂酸辛酯4-甲基苯亚甲基樟脑B相丙二醇视黄酸脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯 | %w/wa3.002.0010.001.002.000.010.105.002.002.000.02510.0010.002.000.075.001.000.100.100.10 |
21 | 脱矿物质水qba | 100.00 |
制备方法:加热A相到75℃;加热C相到+75℃;伴随搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后加入B相继续搅拌并冷却到25℃。
制剂5-水包油乳剂
N°010203040506070891011121314151617181920 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Tocopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯乳酸乙酯B相丙二醇壬二酸脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | %w/wa3.002.0010.001.002.000.010.105.002.0015.010.0010.002.000.075.001.000.100.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
制剂6-水包油乳剂
N°010203040506070891011121314151617181920 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Tocopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯丙酮酸乙酯B相丙二醇过氧化苯(benzoyl peroxide)脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | %w/wa3.002.0010.001.002.000.010.105.002.005.0010.0010.002.000.075.001.000.100.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
制剂7-水包油乳剂
N°010203 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚 | %w/wa3.002.0010.00 |
040506070891011121314151617181920 | 生育乙酸(Tocopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯视黄酸B相丙二醇乳酸脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | 1.002.000.010.100.022.0010.0010.0010.002.000.075.001.000.100.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
制剂8-水包油乳剂
N°0102030405060708910 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Tocopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯丙酮酸乙酯B相丙二醇Adapalene | %w/wa3.002.0010.001.002.000.010.105.002.000.20 |
11121314151617181920 | 脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | 10.0010.002.000.075.001.000.100.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C组合相以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
制剂9-水包油乳剂
N°010203040506070891011121314151617 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Tocopheryl acetate)加州希蒙得木油(Joioba oil)Bht棕榈酸抗坏血酸酯丙酮酸乙酯B相丙二醇乳酸脱矿物质水C相二甲砜丙二醇EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯 | %w/wa3.002.0010.001.002.000.010.105.002.0010.0010.0010.002.000.075.001.000.10 |
181920 | 羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | 0.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
制剂10-水包油乳剂
N°010203040506070891011121314151617181920 | 描述A相streareth 2streareth 21Ppg 15硬脂基醚生育乙酸(Tocopheryl acetate)加州希蒙得木油(Jojoba oil)Bht棕榈酸抗坏血酸酯丙酮酸乙酯B相丙二醇乳酸脱矿物质水C相二甲砜甲硝唑EDTA二钠甘油苯氧乙醇羟苯甲酸甲酯羟苯甲酸乙酯羟苯甲酸丙酯脱矿物质水qba | %w/wa3.002.0010.001.002.000.010.105.002.0010.0010.0010.002.000.075.001.000.100.100.10100 |
制备方法:加热A相到75℃;加热C相到+75℃;不停搅拌将A相和C相组合以制备均匀的溶液;冷却到+45℃;然后与B相组合继续搅拌并冷却到25℃。
图
图1.
暴露于UVB照射之前(曲线a)和之后(曲线b)获得的皮肤的反射光谱。
X轴-波长(nm)
图2
未处理的位点(对照)和用制剂SALDMS 5处理的位点获得的红斑指数的变化量(ΔI.E.)作为时间的函。
Y轴-ΔI.E.
X轴-时间(小时)
图的说明一对照,SALDMS5,#RIFI
图3
使用制剂SALDMS5和使用安慰剂获得的皮肤红斑抑制的百分比(P.I.E.)。
Y轴-P.I.E
X轴-SALDMS5,安慰剂
Claims (10)
1.二甲砜在制备局部使用的药物或化妆品组合物中的应用,以预防和/或治疗由化学、物理、细菌和病毒因子诱导的皮肤刺激,以及用于能够减轻天然产生的或人工来源的日光辐射和A、B和C型紫外照射诱导的损伤的特定光保护作用。
2.权利要求1的应用,用于抑制由选自如下的物理因素诱导的红斑:尤其是与日光过滤剂有关的紫外线照射(日光辐射),电离辐射,x-射线,γ-射线,各种强度和性质的激光。
3.权利要求1的应用,用于减轻由选自如下的化学试剂引起的皮肤刺激:羧酸,二羧酸,三羧酸,单羧酸α羟酸,二羧酸α羟酸,三羧α羟酸,单羧酸β羟酸,二羧酸β羟酸,三羧酸β羟酸,间苯二酚,酚,视黄酸,adapalene,壬二酸,水杨酸,三氯乙酸,过氧化苯及其他可用于化妆品和/或药物领域的物质,特征在于其作为潜在的刺激物。
4.局部使用的药物和/或化妆品组合物,包含药物有效量的二甲砜。
5.如权利要求4所述的组合物,其中所述二甲砜以从0.5%到90%的重量百分比存在。
6.如权利要求5所述的组合物,其中所述二甲砜以从5%到60%,优选在8%和30%之间的重量百分比存在。
7.权利要求4到6任一项的组合物,所述组合物是抗红斑或抗刺激物,其中所述二甲砜以按重量计0.5%到80%之间的变量存在,优选按重量计在1%到20%之间。
8.权利要求4到6任一项的组合物,所述组合物是含有角质层分离剂用于化学换肤的制剂,其中所述二甲砜以按重量计1%到60%之间的量存在,并且所述角质层分离剂的存在量按重量计在5%到70%之间。
9.权利要求4到6任一项的组合物,所述组合物是含有日光过滤剂的制剂,其中所述二甲砜以按重量计0.5%到50%之间的量存在,并且日光过滤剂的存在量按重量计在1%到20%之间。
10.如权利要求9所述的组合物,其中所述日光过滤剂选自PABA,甲基水杨醇,樟脑,苯甲烃铵,硫酸二甲酯,二苯甲酮-3,苯基苯并咪唑磺酸,丁基甲氧基二苯甲酰基甲烷,对苯二亚甲基二樟脑磺酸,苯亚甲基樟脑磺酸,氰双苯丙烯酸辛酯,甲氧基肉桂酸辛酯,聚丙烯酰胺甲基苯亚甲基,PEG-25PABA,水杨酸辛酯,辛基二甲基PABA,p-甲氧基肉桂酸异戊酯,苯甲酮-4,3-苯亚甲基樟脑,4-甲基苯亚甲基樟脑,水杨酸异丙基苯甲酯,辛基triazonesia。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2003/000340 WO2004105741A1 (en) | 2003-05-30 | 2003-05-30 | Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1771028A true CN1771028A (zh) | 2006-05-10 |
Family
ID=33485485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038265672A Pending CN1771028A (zh) | 2003-05-30 | 2003-05-30 | 用于治疗或预防刺激、发炎和皮肤红斑的含二甲砜的化妆品和/或药物组合物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070009451A1 (zh) |
EP (1) | EP1641443B1 (zh) |
JP (1) | JP2006525951A (zh) |
CN (1) | CN1771028A (zh) |
AT (1) | ATE420631T1 (zh) |
AU (1) | AU2003238687B8 (zh) |
CA (1) | CA2525692A1 (zh) |
DE (1) | DE60325904D1 (zh) |
ES (1) | ES2322345T3 (zh) |
HR (1) | HRPK20050965B3 (zh) |
TW (1) | TW200500059A (zh) |
WO (1) | WO2004105741A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104519861A (zh) * | 2012-06-04 | 2015-04-15 | 整体护肤有限责任公司 | 治疗皮肤炎症和相关综合征的化妆美容用和/或药用组合物 |
CN113491644A (zh) * | 2020-04-01 | 2021-10-12 | 株式会社爱茉莉太平洋 | 添加剂组合物以及丙酮酸或者丙酮酸盐的用途 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1631248A1 (en) * | 2003-05-30 | 2006-03-08 | Gianfranco De Paoli Ambrosi | A formulation for chemical peeling |
ITBS20040068A1 (it) * | 2004-05-24 | 2004-08-24 | Gen Topics Srl | Composizione cosmetica e/o farmaceutica per il trattamento della rosacea |
EP1932524A1 (en) * | 2006-12-13 | 2008-06-18 | Ludwig-Maximilians-Universität München | Pharmaceutical preparations for treating inflammatory diseases |
JP2008291032A (ja) * | 2008-06-04 | 2008-12-04 | Paoli Ambrosi Gianfranco De | ケミカルピーリングのための処方 |
JP5753089B2 (ja) * | 2008-10-20 | 2015-07-22 | ドウ ファーマシューティカル サイエンシーズ、インク. | 過酸化ベンゾイルの安定分散液を得る方法 |
ES2958132T3 (es) * | 2018-04-09 | 2024-02-02 | Noon Aesthetics M R Ltd | Formulaciones tópicas que comprenden estroncio y metilsulfonilmetano (MSM) y su uso para el tratamiento de la piel |
WO2023177625A1 (en) * | 2022-03-14 | 2023-09-21 | Blue Hill Technologies Llc | Shelf-stable formulations of benzoyl peroxide and methods of producing same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4974793A (en) * | 1992-09-04 | 1994-03-29 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide |
AU4974693A (en) * | 1992-09-04 | 1994-03-29 | Aws Shakir Mustafa Salim | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid |
GB9218701D0 (en) * | 1992-09-04 | 1992-10-21 | Salim Aws S M | Housewife dermatitis treatment |
WO1994005293A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol |
US6399093B1 (en) * | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
US6653352B2 (en) * | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6328987B1 (en) * | 2000-11-03 | 2001-12-11 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions containing alpha interferon |
NL1017333C2 (nl) * | 2001-02-12 | 2002-08-13 | Gent Natural Products Van | Cosmetisch resp. farmaceutisch preparaat. |
ITBS20040068A1 (it) * | 2004-05-24 | 2004-08-24 | Gen Topics Srl | Composizione cosmetica e/o farmaceutica per il trattamento della rosacea |
-
2003
- 2003-05-30 AT AT03733017T patent/ATE420631T1/de not_active IP Right Cessation
- 2003-05-30 WO PCT/IT2003/000340 patent/WO2004105741A1/en active Application Filing
- 2003-05-30 US US10/557,925 patent/US20070009451A1/en not_active Abandoned
- 2003-05-30 AU AU2003238687A patent/AU2003238687B8/en not_active Ceased
- 2003-05-30 DE DE60325904T patent/DE60325904D1/de not_active Expired - Lifetime
- 2003-05-30 ES ES03733017T patent/ES2322345T3/es not_active Expired - Lifetime
- 2003-05-30 CA CA002525692A patent/CA2525692A1/en not_active Abandoned
- 2003-05-30 JP JP2005500190A patent/JP2006525951A/ja active Pending
- 2003-05-30 EP EP03733017A patent/EP1641443B1/en not_active Expired - Lifetime
- 2003-05-30 CN CNA038265672A patent/CN1771028A/zh active Pending
-
2004
- 2004-05-20 TW TW093114249A patent/TW200500059A/zh unknown
-
2005
- 2005-11-18 HR HR20050965A patent/HRPK20050965B3/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104519861A (zh) * | 2012-06-04 | 2015-04-15 | 整体护肤有限责任公司 | 治疗皮肤炎症和相关综合征的化妆美容用和/或药用组合物 |
CN113491644A (zh) * | 2020-04-01 | 2021-10-12 | 株式会社爱茉莉太平洋 | 添加剂组合物以及丙酮酸或者丙酮酸盐的用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2003238687A1 (en) | 2005-01-21 |
HRPK20050965B3 (en) | 2007-11-30 |
TW200500059A (en) | 2005-01-01 |
CA2525692A1 (en) | 2004-12-09 |
ATE420631T1 (de) | 2009-01-15 |
US20070009451A1 (en) | 2007-01-11 |
WO2004105741A1 (en) | 2004-12-09 |
AU2003238687B8 (en) | 2009-08-06 |
DE60325904D1 (de) | 2009-03-05 |
ES2322345T3 (es) | 2009-06-19 |
EP1641443A1 (en) | 2006-04-05 |
EP1641443B1 (en) | 2009-01-14 |
JP2006525951A (ja) | 2006-11-16 |
HRP20050965A2 (en) | 2006-06-30 |
AU2003238687B2 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100876742B1 (ko) | 피부 건전화제 | |
CN1547475B (zh) | 含电子转移试剂的磷酸酯衍生物的皮肤制剂 | |
CN108670878B (zh) | 抗皮肤过敏的化妆品组合物 | |
CN1942169A (zh) | 用防晒产品处理皮肤的美容方法以及防晒产品组合 | |
AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
AU2017259057B2 (en) | Saxifraga extracts for cosmetic or therapeutic use on the skin | |
CN110325246B (zh) | 防晒组合物 | |
IL190162A (en) | A method of making a cosmetic and / or dermatological preparation for skin protection | |
JPH07145067A (ja) | 外用薬として使用するアンチ・フリーラジカルを使用した化粧品または医薬品の組成物 | |
EP0859589A1 (en) | Skin moisturizing and protective cosmetic compositions | |
HRP20050965A2 (en) | Cosmetic and/or pharmaceutical compositions comprising dimethylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema | |
McDaniel et al. | Evaluation of the antioxidant capacity and protective effects of a comprehensive topical antioxidant containing water-soluble, enzymatic, and lipid-soluble antioxidants | |
WO2001021148A1 (de) | No-freisetzende topisch applizierbare zusammensetzung als biologisches mittel, deren herstellung und deren verwendung als dermatika und/oder kosmetika | |
KR101892079B1 (ko) | 여드름 개선용 조성물 및 이를 포함하는 여드름 개선용 키트 | |
CN108014060B (zh) | 一种防晒增效组合物及其应用 | |
CN111991257A (zh) | 一种防晒增效组合物及其在制备化妆品中的应用 | |
KR101509603B1 (ko) | 미백용 또는 항노화용 피부 외용제 조성물 | |
CN112773738A (zh) | 一种保湿舒缓组合物,其制备方法、护肤品及应用 | |
CN1263762A (zh) | 化妆品组合物和降低皮肤老化过程的方法 | |
Widowati et al. | Potential antiaging activity of secretome gel of human Wharton’s jelly mesenchymal stem cells (hWJ-MSCs) in UV-induced mice models | |
RU2336867C2 (ru) | Композиция для дермального применения, обладающая фотозащитным и антиэритемным действием, содержащая солнечный фильтр и диметилсульфон | |
EP4327824A1 (en) | A topical composition comprising chlorine e6 and zinc l-pyroglutamate | |
CN111956513A (zh) | 一种防晒乳及其制备方法 | |
US20160106723A1 (en) | Methods to sense and treat subclinical skin damage | |
CN1476822A (zh) | 锌金属硫蛋白防晒化妆品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20060510 |